RT Journal
A1 Kuehn BM
T1 STudies shed light on risks and trends in pediatric antipsychotic prescribing
JF JAMA
JO JAMA
YR 2010
FD May 19
VO 303
IS 19
SP 1901
OP 1903
DO 10.1001/jama.2010.596
UL http://dx.doi.org/10.1001/jama.2010.596
AB 
Until recently, only two atypical antipsychotic drugs were approved by the US Food and Drug Administration (FDA) for use in children and adolescents. Risperidone was approved for use in patients aged 13 to 17 years with schizophrenia, patients aged 10 to 17 years for manic or mixed episodes associated with bipolar disorder, and patients aged 5 to 16 years for irritability associated with autism. Aripiprazole was approved to treat schizophrenia in individuals aged 13 to 17 years, and for use alone or as an adjunct to lithium or valproate in individuals aged 10 to 17 years with bipolar mania.